Plum SEC
Menu
Korean Market
Privacy Policy
Korean Market
Star Rating
Reset (View All)
★★★★★
★★★★
★★★
★★
★
★
★
★★
★★★
★★★★
★★★★★
All Disclosures
Search
EXCH
PharmGen Science
★
PharmGen Science Discloses Governance Report: 80% Non-compliance of Key Indicators, Massive Net Loss Raises Shareholder Concerns
06/01/2026, 04:03 PM
PERI
PharmGen Science
★
PharmGen Science: Q1 2026 Operating Profit Up but Net Loss Continues
05/15/2026, 03:37 PM
PERI
PharmGen Science
★★★
PharmGen Science Posts 116.6B KRW Net Loss Due to Impairment of Equity Method Investments; Assets Down 46%
05/15/2026, 03:24 PM
OWNR
PharmGen Science
★
Submission of Report on Ownership of Specific Securities by Executives and Major Shareholders
05/12/2026, 04:35 PM
OWNR
PharmGen Science
★
Submission of Large Shareholding Report Form (No Content)
05/12/2026, 04:18 PM
EXCH
PharmGen Science
★
PharmGen Science: Largest Shareholder Stake Rises from 19.88% to 20.31% (CB Conversion etc.)
05/12/2026, 04:07 PM
EXCH
PharmGen Science
★
699,863 New Shares Issued upon Conversion of Convertible Bonds (3.18% Dilution)
05/12/2026, 04:04 PM